PHASE 2,ADAPTIVE,DOUBLE-BLINDED,PLACEBO-CONTROLLED,RANDOMIZED,MULTI-CENTER TRIAL TO EVALUATE THE EFFICACY,SAFETY AND TOLERABILITY OF INTRACORONARY INFUSION OF AB-1002 IN ADULT SUBJECTS WITH NYHA CLASS III HEART FAILURE AND NON-ISCHEMIC CARDIOMYOPATHY

Registry ID

ASK-CHF2-CS201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ASKLEPIOS BIOPHARMACEUTICAL, INC.

Start date

2025-02-24

Last update

2024-12-13

Conditions

• CARDIOMYOPATHY

Related clinical trials

• A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY)
• OPEN-LABEL EXTENSION STUDY OF LONG-TERM SAFETY AND EFFICACY OF NNC6019-0001 IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM)
• TARGETED THERAPY WITH GLYCOGEN SYNTHASE KINASE-3 INHIBITION FOR ARRHYTHMOGENIC CARDIOMYOPATHY (TARGET)

View on source registry